Traditional cancer therapies include surgery, radiation, and chemotherapy, all of which are typically nonspecific approaches. Cancer immunotherapy is a type of cancer treatment that helps the immune system fight cancer. Cancer immunotherapy represents a standing example of precision medicine: immune checkpoint inhibitors precisely target the checkpoints; tumor infiltrating lymphocytes, TCR T cells, and CAR T cells precisely kill cancer cells through tumor antigen recognition; and cancer vaccines are made from patient-derived dendritic cells, tumor cell DNA, or RNA, or oncolytic viruses, thus offering a type of personalized medicine. This review will highlight up-to-date advancement in most, if not all, of the immunotherapy strategies.
Introduction
Recent FDA approval of immune checkpoint inhibitors and T lymphocytes expressing chimeric antigen receptors (CAR T) for cancer therapy signifies an unprecedented success in cancer immunotherapy. Cancer immunotherapy would not have reached such a milestone without advances in the area of cancer immunology. During tumor development, the immune system constantly engages with tumor cells, which undergo three phases: elimination, equilibrium, and escape.
In the elimination/immunosurveillance phase, effector immune cells, particularly effector T cells, are able to kill cancer cells on recognition of tumor antigens. In support, T cells specific for tumor antigens predicted by cutting edge tumor genome sequencing, have been detected in patients with melanoma. 1 Patients with pre-existing antitumor immunity at diagnosis and patients with more tumor infiltrating T cells show longer survival. 2 Moreover, it has been suggested that effector immune cells exist in premalignant lesions to counteract danger signals. 2 In the equilibrium phase, effector immune cells are balanced by immune suppressive mechanisms (e.g. regulatory T cells (Treg)), which prevent progression of the premalignant lesion. In the escape phase, immune suppressive mechanisms outcompete effector immune cells, leading to cancer immune evasion and tumor formation. 2, 3 In this review, we outline mechanisms of cancer immune evasion and strategies of immunotherapy that are currently being used or explored to counteract cancer immune evasion. At the end of the review, we discuss future directions for cancer immunotherapy.
Mechanisms of cancer immune evasion
T cells need to recognize tumor antigens to kill tumor cells. Thus, one important mechanism of tumor immune evasion is that tumor cells downregulate their antigen processing/presentation machinery, such as the major histocompatibility complex (MHC) I, proteosome subunit latent membrane protein (LMP) 2 and LMP7, transporter associated with antigen processing (TAP) protein, and tapasin, preventing them from being recognized by T cells (Fig. 1) . 3 It is well known that IFNinduced signaling promotes antigen presentation in tumor cells, [4] [5] [6] [7] and, recently, IFN signaling has been shown to be positively regulated by Aplnr and negatively regulated by Ptpn2 and CDK4/6. 4, 5, 7 Therefore, downregulation of IFN signaling/Aplnr or upregulation of Ptpn2/CDK4/6 may dampen antigen presentation and thus contribute to tumor immune evasion. [4] [5] [6] [7] Cancer cells can directly cause T cell exhaustion by facilitating their PD-L1 and B7-1/2 binding to immune checkpoint proteins PD-1 and CTLA-4, respectively, on T cells. 3, 8 Moreover, cancer cells may cause T cell exhaustion by increasing PD-L1 and PD-1 expression (Fig. 1) . 3, 8, 9 As PD-L1 expression is positively regulated by inflammatory signaling (e.g. IFN-γ, LPS, TNF-α), oncogenic signaling (e.g. Myc, Cdk5, Ras), and CMTM6-and CDK4-mediated post-translational stabilization, 10 upregulation of these signals could contribute to T cell exhaustion. Because deficiency in kelch-like ECH-associated protein 1 (KEAP1) and PTEN in lung adenocarcinoma has been shown to promote PD-L1 expression, 11 T cell exhaustion may be attributable to downregulation of KEAP/PTEN. Another mechanism of cancer immune evasion is attributed to secretion of immune suppressive modulators (e.g. TGF-β, IL-8, IL-10, IL-18, CSF1, VEGF, gangliosides, ROS, Kynurenines, K + ) into the tumor microenvironment (TME) by tumor cells. These immune suppressive modulators can dampen T cell function and/or dendritic cell (DC) maturation, leading to defective cross-presentation of tumor antigens to T cells. (TGF-β, IL-8, IL-10, IL-18, CSF1 , VEGF, gangliosides, ROS, Kynurenines, K + ) and metabolites (adenosine, PGE, lactate) into TME, (iv) deprivation of immune activating metabolites (glucose, arginine, glutamine, tryptophan) from TME, (v) recruitment and/or activation of Treg, MDSC and TAM, and (vi) inhibition of effector T cell infiltration.
Tumor cells may dampen T cell function by altering metabolic composition in the TME. For example, tumor cells decrease oxygen, pH, glucose, and amino acids (e.g. glutamine, tryptophan, arginine) which promote T cell function, and increase adenosine, prostaglandin E (PGE), and lactate which inhibit T cell function. [13] [14] [15] [16] [17] It is known that tumor cells harboring B-RAF mutations show enhanced glycolysis, leading to decreased glucose availability in TME. 18 Moreover, immune suppressive cell populations in TME constitute a critical mechanism of T cell dysfunction. 3 These cells include Treg that can be activated by suppressive modulators (e.g. TGF-β, IL-10, gangliosides) and metabolites (e.g. PGE), myeloidderived suppressor cells (MDSC), and tumor-associated macrophages (TAM). 3 Last but not the least, tumor cells may repress T cell recruitment to tumor sites ( Fig. 1) . 19, 20 Cancer immunotherapy strategies
Numerous cancer immunotherapy strategies are under investigation. A few have been approved for cancer treatment. For the ease of review, we classify these as molecular therapy, cellular therapy, and vaccination therapy.
Molecular therapy
Cytokine IL-2 functions to promote T cell growth. IL-2 has been approved by the FDA for treatment of metastatic renal cell carcinoma (RCC) and metastatic melanoma. 21 IL-2 combined with EGFR TKI gefitinib has shown improved outcome in patients with advanced non-small-cell lung cancer (NSCLC). 22 IL-2 is used to expand autologous tumor infiltrating lymphocytes (TIL), lymphocytes expressing transgenic TCRs (TCR T), and CAR T in vitro, and to support their growth and survival after adoptive transfer into cancer patients. 21 Nonetheless, caution must be taken with use of IL-2, because it can also promote Treg proliferation and yield severe toxicities, including vascular leak syndrome (VLS), pulmonary edema, hypotension, and heart toxicities (Table 1) . 23 TIL become exhausted because of upregulation of a number of immune checkpoint proteins such as PD-1, CTLA-4, Tim-3, and LAG-3, and because of the interaction between PD-1 and tumoral PD-L1 and between CTLA-4 and tumoral B7-1/2. 3, 8, 24 The FDA-approved anti-CTLA-4 (ipilimumab), anti-PD-1 (nivolumab and pembrolizumab), and anti-PD-L1 (atezolizumab, avelumab, and durvalumab) block the inhibitory function and the interaction of these checkpoint proteins to reactivate T cells. Ipilimumab, nivolumab, and pembrolizumab were approved for treating melanoma. Nivolumab and pembrolizumab were also approved for treating lung cancer. Anti-LAG-3 may also boost T cell responses through its effect on DC. 28 Co-stimulatory receptors 4-1BB, OX40, and GITR on T cells play a role in T cell activation. Agonistic anti-4-1BB, anti-OX40, and anti-GITR are being tested for their anti-tumor activities. It has been shown that anti-4-1BB stimulates T cells, whereas anti-OX40 and anti-GITR not only stimulate T cells but also inhibit Treg. [29] [30] [31] Costimulatory molecule CD40 on DC is involved in DC activation. Agonistic anti-CD40 has shown anti-tumor effect through its activation of DC and T cell priming.
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Tumor cells secret a number of immune suppressive factors (e.g. TGF-β, PGE2, IDO, arginase, adenosine) into TME. 3 Targeting these factors may reactivate T cells for anti-tumor immunity. Indeed, suppression of TGF-β or PGE2 production has been shown to restore T cell responses in head and neck squamous cell carcinoma treated with EGFR inhibitor. 33 IDO inhibitors are being tested in clinical trials in patients with pancreatic cancer or other cancers. 34, 35 An arginase inhibitor, CB-1158, is being studied in a phase I clinical trial in patients with advanced solid tumors, 35 and targeting of adenosine pathways or adenosine receptors shows therapeutic effects in preclinical studies. 36 Defects in mitochondrial metabolism compromise TIL function. 22 Thus, targeting metabolic pathways in T cells may benefit cancer patients. A recent study showed that a PPAR-α agonist promotes fatty acid catabolism in CD8 + T cells and enhances CD8 + T cell response against tumors. 37 T cell metabolism has been shown to be regulated by immune checkpoint proteins. For example, CTLA-4 negatively regulates the PI3K/Akt/ mTOR/c-Myc/Hif1α pathway-and co-receptor CD28-mediated glucose uptake and/or glycolysis; and PD-1 inhibits mTOR and PGC-1α metabolic pathways. 22, 38 Thus, blockade of CTLA-4 or PD-1 on CD8 + TIL cells increases their glucose uptake and reinvigorates their function. 38 On the other hand, blockade of PD-L1 on tumor cells dampens glucose uptake and glycolysis of tumor cells, leading to increased glucose availability in TME that also promotes T cell function. 39 
Cellular therapy
Adoptive T cell therapy is a type of therapy involving in vitro expansion of patient-derived tumor antigenspecific T cells and their re-infusion into patients.
Adoptive transfer of TIL has shown promise in patients with metastatic melanoma in a variety of clinical trials. However, because TIL are extremely limited in numbers, generating sufficient TIL cells for adoptive T cell therapy can be complicated and time-consuming. 40, 41 Adoptive transfer of TIL has not shown benefit in other cancers (Table 1) . In this context, peripheral blood T cells may be a better choice. Indeed, blood T cells are used to generate genetically engineered T cells, namely TCR T and CAR T that express transgenic TCRs and CARs, respectively.
TCR T cells that target melanocyte differentiation antigen MART-1 show durable responses in metastatic melanoma. Nonetheless, on target, off-tumor toxicity is apparent in normal melanocytes in the skin, eye, and cochlea. TCR T cells that target cancer-testis antigen MAGE-A3 also cause fatal neurotoxicity and cardiotoxicity. On the other hand, TCR T cells that target cancer-testis antigen NY-ESO-1 display clinical efficacy without obvious toxicities in a phase I/II trial in multiple myeloma patients (Table 1) . 42 TCR T cells that are directed to neoantigens, a type of tumor antigens only expressed in tumor cells but Other drawbacks of CAR T cells include difficulties in penetrating solid tumors, outrageously high cost, and lengthened production ( Table 1 ). Strategies to conquer these pitfalls have been extensively discussed elsewhere. 43, 44 Treg cells constitute a critical suppressive cell population in TME. Treg depletion may thus benefit cancer patients. Denileukin diftitox (trade name: Ontak) is a fusion protein combining IL-2 and diphtheria toxin. On binding to IL-2 receptor CD25 that is enriched on Treg, denileukin diftitox releases diphtheria toxin into Treg, leading to Treg depletion. 45 Denileukin diftitox was approved by the FDA for treating cutaneous T cell lymphoma; however, it was discontinued in 2014 because of production issues. 46 Other strategies to deplete Treg include anti-CD25 antibody-based therapies and chemotherapies (e.g. cyclophosphamide, fludarabine).
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As indiscriminate removal of Treg may cause autoimmune diseases (Table 1) , it may be more advantageous to inhibit Treg function using antibodies against Treg functional markers, such as CTLA-4 and GITR, and/ or to block Treg trafficking to tumor sites using methyl gallate or AMD3100. 47, 48 Given that Treg can be differentiated from naïve T cells or converted from effector T cells, blockade of these processes (e.g. using antibody against TGF-β) may evoke anti-tumor immune responses. 47 In addition, a concept of reprogramming Treg to effector T cells is emerging (Table 1) . 47 Finally, recent transcriptome profiling has revealed that intratumoral Treg express a tumor-specific gene signature (e.g. MAGEH1, IL1R2, TFRC, FCRL3), 49 T-VEC, a HSV vaccine, has been approved by the FDA to treat melanoma patients. Autologous DC pulsed with tumoral peptides/proteins/DNA/mRNA, whole tumor cell lysate, or with intact tumor cells are well-known therapeutic vaccines. 57, 58 Currently, there are more than 200 DC vaccines in clinical trials. 58 Sipuleucel-T, a DCcontained antigen-presenting cell (APC) vaccine derived from patient blood and pulsed with a fusion protein of prostatic acid phosphatase (PAP) and GM-CSF, has been approved by the FDA to treat prostate cancer patients. 59 Finally, human and murine induced pluripotent stem cells (iPSC) expressing tumor-associated antigens may be used as therapeutic vaccines, because they can induce an antigen-specific anti-tumor T cell response. 60 The most significant development in cancer vaccine studies is to include agonists of various innate immune receptors, particularly TLR, to vaccine formulations. These agonists include TLR-3 agonist poly I:C, TLR-4 agonist monophosphoryl lipid A, TLR-5 agonist flagellin, TLR-7 agonist imiquimod, and TLR-9 agonist CpG. 61 A major challenge in cancer vaccine development is how to generate strong and long-lasting anti-tumor immunity, which may be achieved by optimal delivery of wellchosen tumor-associated antigens. The advantages and disadvantages of cancer vaccination are exemplified in Table 1 . Readers are referred to a recent publication for further information. 60 
Immunotherapy drug resistance and combination therapy
Among all of the immunotherapy strategies aforementioned, immune checkpoint inhibitors have received the most attentions. As monotherapies, these inhibitors have shown long-term benefits in 40% of melanoma patients, 80% of Hodgkin's lymphoma patients, and 50% of Merkel cell carcinoma patients. 62 However, immune checkpoint inhibitors, as well as CAR T cells and other immunotherapies that are being used in clinics, do not benefit the majority of cancer patients. In addition, many patients who initially benefit from these therapies develop acquired resistance. The mechanisms that underlie primary resistance include: (i) low antigenic mutations in tumor cells, (ii) aberrant expression of genes in tumor cells that promote mesenchymal transition, cell adhesion, extracellular matrix remodeling, angiogenesis, wound healing, and immunosuppression (e.g. IL-10), 63 and (iii) downregulation of IFN-α receptor 1 in CD8 + T cells. 64 The mechanisms that underlie acquired resistance include: (i) loss of target antigen expression in tumor cells (in the case of adoptive T cell transfer), 65 (ii) increased expression of immune checkpoint ligands on tumor cells, and (iii) accumulation of immunosuppressive cells such as Treg in TME. 38 Furthermore, primary and acquired resistance may be explained by some common mechanisms, for instance, tumor cell-intrinsic defects in the antigen presentation machinery and in IFN-γ/IFN-γ receptor signaling pathway and T cell-intrinsic expression pattern of immune checkpoint proteins. 6, 66 For the latter, primary resistance may be result from T cell dysfunction mediated by multiple checkpoint proteins (e.g. PD-1, CTLA-4, Lag-3, Tim-3), and thus is not reversible by sole blockade of the PD-1/PD-L1 axis or CTLA-4, whereas acquired resistance may result from T cell reinvigoration-induced IFN-γ increases in tumor MHC expression/antigen presentation and thus enhanced TCR signaling, leading to upregulation of alternative immune checkpoints (e.g. Tim-3, Lag-3, TIGIT) on T cells.
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A major approach to overcome immunotherapy drug resistance is combination therapy. 65 There are more than 1100 clinical trials on combination therapy that combine an immune checkpoint inhibitor with: (i) chemotherapy, radiation, molecularly targeted therapy (e.g. HDAC inhibitor, CDK4/6 inhibitor), or metabolic therapy (e.g. MCT1 inhibitor, agonistic anti-4-1BB) that may not only shrink tumor mass but also induce ICD, leading to DAMP response-mediated DC activation and subsequent tumor antigen cross-presentation, (ii) a pattern recognition receptor (PRR) agonist (e.g. STING agonist), (iii) co-stimulatory signals on APC (e.g. anti-CD40), and (iv) adoptive T cell transfer (CAR T or TCR T), oncolytic viruses, or vaccines that target neoantigens. Dual checkpoint blockade (e.g. anti-CTLA-4 + anti-PD-1, anti-CTLA-4 + anti-Tim-3) is also being tested. [67] [68] [69] The FDA has approved the combination of anti-PD-1 (nivolumab) with anti-CTLA-4 (ipilimumab) for treating metastatic melanoma, and the combination of anti-PD-1 (pembrolizumab) with chemotherapy drugs pemetrexed and carboplatin to treat metastatic NSCLC. In addition to combination therapies that involve immune checkpoint inhibitor(s), combined agonistic anti-CD40 and CSF-1R inhibitor have recently been shown to suppress melanoma growth through simultaneous targeting of DC and tumor-associated macrophages (TAM). 70 As T cells in TME usually lose metabolic competitiveness (e.g. decreased glucose uptake and glycolysis) and supplementation of pyruvate, the final product of glycolysis, can increase TIL activation and function in clear cell RCC, 71 an agent that increases metabolic competitiveness of T cells combined with cancer vaccines or adoptive T cell transfer may achieve satisfactory efficacy. 24 
Prediction of responsiveness of cancer patients to immunotherapy
The efficacies of current immunotherapy drugs vary considerably from patient to patient, highlighting the importance of identifying personalized biomarkers to predict who is likely to respond to a specific therapy. A number of biomarkers have been identified: (i) High mutational loads correlate with good drug response. For example, melanoma, NSCLC, bladder cancer, gastric cancer, and squamous cell carcinoma of the head and neck (SCCHN) that bear high mutational loads have high response rate to anti-PD1, whereas pancreatic and prostate cancer that harbor low mutational loads show poor response to anti-PD1. 71 However, there is at least one exception: RCC has a modest number of mutations but is reasonably sensitive to checkpoint inhibitors.
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(ii) Tumors showing high levels of PD-1 and/or PD-L1 are generally sensitive to anti-PD-1/PD-L1 treatment. 5, 85 These small molecules as immunotherapy drugs are supposedly more advantageous than biologics (e.g. antibodies, CAR T), because they can (i) target intracellular pathways, (ii) induce acute anti-tumor effects and avoid systemic immunogenicity, thereby improving therapeutic index, (iii) easily penetrate solid tumors, (iv) be orally administered allowing flexible dosing, and (v) be cost-effective. 86, 87 On the one hand, identification of biomarkers for prediction of patient response to immunotherapy drugs is essential. Moreover, it is equally important to develop appropriate experimental models to test drug responsiveness. In this aspect, a number of mouse models have been established; 44 however, each of them have drawbacks. 44 That being said, patient-derived xenografts (PDX) with tumor tissues orthotopically implanted or patient-derived organoids co-cultured with lymphocytes may be a better option. 88 Finally, recently published Pan-Cancer Atlas data could not only advise mutational loads and neoantigen abundance of a given tumor type that are positively correlated with patient response to immune checkpoint inhibitors, but also predict driver mutations that may be used to develop personalized immunotherapies such as vaccines, tumor-specific T cells, and CAR T cells. 89 
